These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 10023944)

  • 1. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators.
    Lancet; 1999 Jan; 353(9146):14-7. PubMed ID: 10023944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modest effect of interferon alfa on metastatic renal-cell carcinoma.
    Amato R
    Lancet; 1999 Jan; 353(9146):6-7. PubMed ID: 10023941
    [No Abstract]   [Full Text] [Related]  

  • 3. Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN).
    Atzpodien J; Schmitt E; Gertenbach U; Fornara P; Heynemann H; Maskow A; Ecke M; Wöltjen HH; Jentsch H; Wieland W; Wandert T; Reitz M;
    Br J Cancer; 2005 Mar; 92(5):843-6. PubMed ID: 15756254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.
    Escudier B; Pluzanska A; Koralewski P; Ravaud A; Bracarda S; Szczylik C; Chevreau C; Filipek M; Melichar B; Bajetta E; Gorbunova V; Bay JO; Bodrogi I; Jagiello-Gruszfeld A; Moore N;
    Lancet; 2007 Dec; 370(9605):2103-11. PubMed ID: 18156031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. On the development of the Medical Research Council trial of alpha-interferon in metastatic renal carcinoma. Urological Working Party Renal Carcinoma Subgroup.
    Fayers PM; Cook PA; Machin D; Donaldson N; Whitehead J; Ritchie A; Oliver RT; Yuen P
    Stat Med; 1994 Nov; 13(21):2249-60. PubMed ID: 7846423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.
    Flanigan RC; Salmon SE; Blumenstein BA; Bearman SI; Roy V; McGrath PC; Caton JR; Munshi N; Crawford ED
    N Engl J Med; 2001 Dec; 345(23):1655-9. PubMed ID: 11759643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.
    Hudes G; Carducci M; Tomczak P; Dutcher J; Figlin R; Kapoor A; Staroslawska E; Sosman J; McDermott D; Bodrogi I; Kovacevic Z; Lesovoy V; Schmidt-Wolf IG; Barbarash O; Gokmen E; O'Toole T; Lustgarten S; Moore L; Motzer RJ;
    N Engl J Med; 2007 May; 356(22):2271-81. PubMed ID: 17538086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial.
    Mickisch GH; Garin A; van Poppel H; de Prijck L; Sylvester R;
    Lancet; 2001 Sep; 358(9286):966-70. PubMed ID: 11583750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon alpha 2b as medical selection for nephrectomy in patients with synchronous metastatic renal cell carcinoma: a consecutive study.
    Bex A; Kerst M; Mallo H; Meinhardt W; Horenblas S; de Gast GC
    Eur Urol; 2006 Jan; 49(1):76-81. PubMed ID: 16310929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is treatment with interferon-alpha effective in all patients with metastatic renal carcinoma? A new approach to the investigation of interactions.
    Royston P; Sauerbrei W; Ritchie A
    Br J Cancer; 2004 Feb; 90(4):794-9. PubMed ID: 14970855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party.
    van Herpen CM; Jansen RL; Kruit WH; Hoekman K; Groenewegen G; Osanto S; De Mulder PH
    Br J Cancer; 2000 Feb; 82(4):772-6. PubMed ID: 10732744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytokine therapy response as a selection criterion for cytoreductive nephrectomy in metastatic renal clear-cell carcinoma of intermediate prognosis. Results and conclusions from a combined analysis.
    Bex A; Haanen JB; Vyth-Dreese FA; Horenblas S; de Gast GC
    Urol Int; 2008; 80(4):367-71. PubMed ID: 18587246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon alfa and vinblastine versus medroxyprogesterone acetate in the treatment of metastatic renal cell carcinoma.
    Kriegmair M; Oberneder R; Hofstetter A
    Urology; 1995 May; 45(5):758-62. PubMed ID: 7747370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subcutaneous interleukin-2 and interferon alfa administration in patients with metastatic renal cell carcinoma: final results of SCAPP III, a large, multicenter, phase II, nonrandomized study with sequential analysis design--the Subcutaneous Administration Propeukin Program Cooperative Group.
    Tourani JM; Pfister C; Tubiana N; Ouldkaci M; Prevot G; Lucas V; Oudard S; Malet M; Cottu P; Ferrero JM; Mayeur D; Rixe O; Sun XS; Bernard O; Andre T; Tournigand C; Muracciole X; Guilhot J;
    J Clin Oncol; 2003 Nov; 21(21):3987-94. PubMed ID: 14581421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of combination interferon-alpha and thalidomide as first-line therapy in metastatic renal cell carcinoma.
    Clark PE; Hall MC; Miller A; Ridenhour KP; Stindt D; Lovato JF; Patton SE; Brinkley W; Das S; Torti FM
    Urology; 2004 Jun; 63(6):1061-5. PubMed ID: 15183950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subcutaneous administration of interferon alpha and gamma in patients with metastatic renal cell carcinoma.
    Koga S; Nishikido M; Matsuya F; Kanetake H; Saito Y
    Anticancer Res; 1999; 19(6C):5547-50. PubMed ID: 10697614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial.
    Gore ME; Griffin CL; Hancock B; Patel PM; Pyle L; Aitchison M; James N; Oliver RT; Mardiak J; Hussain T; Sylvester R; Parmar MK; Royston P; Mulders PF
    Lancet; 2010 Feb; 375(9715):641-8. PubMed ID: 20153039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized phase II study comparing thalidomide with medroxyprogesterone acetate in patients with metastatic renal cell carcinoma.
    Lee CP; Patel PM; Selby PJ; Hancock BW; Mak I; Pyle L; James MG; Beirne DA; Steeds S; A'Hern R; Gore ME; Eisen T
    J Clin Oncol; 2006 Feb; 24(6):898-903. PubMed ID: 16484699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [High-dose medroxyprogesterone acetate in the treatment of metastatic carcinoma of renal parenchyma].
    Popov I; Jelić S; Milanović N; Kovcin V; Vuletić Lj
    Srp Arh Celok Lek; 1996; 124(3-4):73-6. PubMed ID: 9102823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicenter phase II trial of interleukin-2, interferon-alpha, and 13-cis-retinoic acid in patients with metastatic renal-cell carcinoma.
    Stadler WM; Kuzel T; Dumas M; Vogelzang NJ
    J Clin Oncol; 1998 May; 16(5):1820-5. PubMed ID: 9586896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.